Checkpoint Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights
August 05, 2020 16:30 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company focused on the acquisition,...
Checkpoint Therapeutics to Present Cosibelimab Interim Results from Registration-Enabling Trial at ESMO Virtual Congress 2020
July 27, 2020 07:30 ET
|
Checkpoint Therapeutics, Inc
Presentation to highlight updated interim data from global trial in patients with metastatic cutaneous squamous cell carcinomaOver 50% of enrollment target achieved; full enrollment expected around...
Checkpoint Therapeutics to Host Virtual Annual Meeting of Stockholders
May 22, 2020 08:30 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, May 22, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it will...
Checkpoint Therapeutics Reports First Quarter 2020 Financial Results and Recent Corporate Highlights
May 06, 2020 16:30 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, May 06, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company focused on the acquisition,...
Checkpoint Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Anti-PD-L1 Antibody Cosibelimab
April 21, 2020 08:00 ET
|
Checkpoint Therapeutics, Inc
- U.S. patent protection through at least May 2038- Registration-enabling study of cosibelimab in cutaneous squamous cell carcinoma over one-third enrolled NEW YORK, April 21, 2020 (GLOBE NEWSWIRE)...
Checkpoint Therapeutics Reports Full-Year 2019 Financial Results and Recent Corporate Highlights
March 11, 2020 16:15 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition,...
Checkpoint Therapeutics Announces Confirmation of Registration Path for Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma
January 13, 2020 08:15 ET
|
Checkpoint Therapeutics, Inc
FDA feedback supports plan to submit Biologics License Application (BLA) based on data from ongoing Phase 1 trialOne-third enrollment complete in cohort of patients with metastatic cutaneous squamous...
Checkpoint Therapeutics Announces Pricing of Public Offering of Common Stock
November 20, 2019 09:20 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the pricing of...
Checkpoint Therapeutics Announces Proposed Public Offering of Common Stock
November 19, 2019 16:01 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it is...
Checkpoint Therapeutics Announces Presentation of Anti-PD-L1 Cosibelimab Data at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 08, 2019 07:30 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that new...